CD274 and non-small cell lung carcinoma: Pooled OR analysis revealed that anti-PD-L1 agents in urothelial cancer had a higher risk of irAEs (OR: 1.13; 95% CI: 0.86–1.49; p = 0.41), while pembrolizumab in NSCLC caused fewer irAEs than nivolumab (OR: 0.32; 95% CI: 0.32–1.02; p = 0.09).